These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1267 related articles for article (PubMed ID: 10828860)
21. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
22. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813 [TBL] [Abstract][Full Text] [Related]
23. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254 [TBL] [Abstract][Full Text] [Related]
24. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951 [TBL] [Abstract][Full Text] [Related]
25. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W; Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342 [TBL] [Abstract][Full Text] [Related]
27. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521 [TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666 [TBL] [Abstract][Full Text] [Related]
30. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257 [TBL] [Abstract][Full Text] [Related]
31. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931 [TBL] [Abstract][Full Text] [Related]
32. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650 [TBL] [Abstract][Full Text] [Related]
33. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W; J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954 [TBL] [Abstract][Full Text] [Related]